1. Home
  2. Browse
  3. HRA004738
HRA004738
   HRA004738.xlsx
Title:
Transcriptome sequencing based on the phase 2 clinical trial of Camrelizumab combined with apatinib in the treatment of recurrent/metastatic nasopharyngeal carcinoma
Release date:
2023-07-14
Description:
The RNA sequences were performed to explore biomarkers from the tumor immune contexture that potentially predict the antitumor activity of Camrelizumab and apatinib . To explore the mechanism of Camrelizumab combined apatinib for nasopharyngeal carcinoma immunotherapy. To explore the effect of Camrelizumab combined apatinib on tumor microenvironment.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA017383
Study type:
Disease Study
Disease name:
nasopharynx carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC002669
DAC name:
SYSUCC
Contact person:
Jia Guo Dong
Email:
jiagd@sysucc.org.cn
Description:
Applications for access to controlled data are reviewed and authorized in accordance with the consent form and/or national research ethics provisions.
Individuals & samples
Files
Request Data
Submitter:   Mai Hai Qiang / maihq@sysucc.org.cn
Organization:   Sun Yat-sen University Cancer Center
Submission date:   2023-05-31
Requests:   -